Overview


According to FutureWise analysis the market for sexually transmitted infections (STIs) in 2023 is US$ 62.79 billion, and is expected to reach US$ 162.5 billion by 2031 at a CAGR of 12.60%.

Infections transmitted through sexual contact are known as sexually transmitted infections (STIs). Bacteria, viruses, and parasites that cause sexually transmitted diseases can be communicated from one person to another by blood, sperm, vaginal, and other bodily fluids. These infections can be transmitted nonsexually, for example, from mothers to their infants during pregnancy or childbirth, or through blood transfusions or sharing needles. Single-dose antibiotic regimens can treat three bacterial STIs (chlamydia, gonorrhoea, and syphilis) and one parasitic STI (trichomoniasis). The most prevalent mechanism for sexually transmitted infections (STIs) to spread is through unprotected sexual contact. Infected blood or blood products can potentially spread STIs during pregnancy, childbirth, and lactation. Sexually transmitted infections (STIs) have a substantial impact on one's health. If left untreated, they can result in neurological and cardiovascular problems, infertility, ectopic pregnancy, stillbirths, and a higher risk of catching the Human Immunodeficiency Virus (HIV). They've also been related to societal stigma, domestic violence, and a poor standard of living. Aptima is the first and only FDA-approved test for STDs, and it's gaining popularity (STI). Furthermore, the market's expansion is supported by investments in advanced technology development. Furthermore, a lack of public knowledge and consequences associated with the disease, such as pregnancy issues, infertility, pelvic pain, ocular inflammation, arthritis, and others, would act as a restraint and slow down the market's growth rate.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Sexually Transmitted Infections (STIs) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Sexually Transmitted Infections (STIs) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • AstraZeneca.
  • Johnson & Johnson Private Limited
  • MerckCo., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma.
  • Lupin
  • Cipla Inc.
  • Hologic, Inc.
  • BD
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Bausch Health Companies Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Location of Testing

  • Laboratory Testing
  • PCR
  • Immunochromatographic assays
  • Flow Cytometers
  • Differential Light Scattering machines
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Point-of-care (POC) Testing
  • Others

By Type

  • HIV/AIDS
  • Human Papilloma Virus (HPV)
  • Gonorrhea
  • Syphilis
  • Others

By Treatment

  • Antibiotics
  • Antiviral

By Route of Administration

  • Oral
  • Parenteral
  • Other

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Sexually Transmitted Infections (STIs) Market By Location of Testing, By Type, By Treatment, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Sexually Transmitted Infections (STIs) Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Sexually Transmitted Infections (STIs) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Sexually Transmitted Infections (STIs) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Sexually Transmitted Infections (STIs) Market, By Location of Testing Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Laboratory Testing
        2. PCR
        3. Immunochromatographic assays
        4. Flow Cytometers
        5. Differential Light Scattering machines
        6. Enzyme Linked Immunosorbent Assay (ELISA)
        7. Point-of-care (POC) Testing
        8. Others

  • 8.   Sexually Transmitted Infections (STIs) Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. HIV/AIDS
        2. Human Papilloma Virus (HPV)
        3. Gonorrhea
        4. Syphilis
        5. Others

  • 9.   Sexually Transmitted Infections (STIs) Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antibiotics
        2. Antiviral

  • 10.   Sexually Transmitted Infections (STIs) Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral
        3. Others

  • 11.   Sexually Transmitted Infections (STIs) Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 12.   Sexually Transmitted Infections (STIs) Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.   North America Sexually Transmitted Infections (STIs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Sexually Transmitted Infections (STIs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Sexually Transmitted Infections (STIs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Sexually Transmitted Infections (STIs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GlaxoSmithKline plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Mylan N.V.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Sanofi
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson & Johnson Private Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
         9. Merck & Co., Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. F. Hoffmann-La Roche Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Bayer AG
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Eli Lilly and Company
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Sun Pharmaceutical Industries Ltd
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Aurobindo Pharma.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Lupin
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
        16. Cipla Inc.
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Hologic, Inc.
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. BD
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
          19. Bristol-Myers Squibb Company
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
        20. Gilead Sciences, Inc.
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
         21. Bausch Health Companies Inc
          21.1. Company Overview
          21.2. Product Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients